ALL: Combining paediatric-type therapy with minimal residual disease from nilg Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Rambaldi speaks with ecancertv at ASH 2016 about the final results of the Northern Italy Leukaemia Group (NILG) trial combining paediatric-type therapy with minimal residual disease (MRD) review, and risk-oriented haematopoietic cell transplantation (HCT) in adult acute lymphoblastic leukaemia (ALL).nnThe current paediatric-type therapy and MRD-based risk-oriented strategy was applicable to adults with ALL in a wide age range, with some limitations in patients over 60 years.nnMRD was essentia
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)